
|Articles|January 15, 2007
Clinical trial under way for topical AMD therapy
San Diego-TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD).
Advertisement
San Diego-TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD).
The single-site, 45-patient study will test its small-molecule, multitargeted kinase inhibitor TG100801 as a therapy for AMD and other eye diseases.
The eye drop suppresses disease-related edema, angiogenesis, and inflammation. TargeGen expects to complete the phase I study by the end of the first quarter of 2007, with plans to start a phase II trial by mid-year.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
FDA clears Novaliq’s Investigational New Drug application for NOV05
3
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
4
Eye exams could enable earlier detection of systemic disease
5



























